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A B S T R A C T
Introduction. Congenital hypogonadotropic hypogonadism (CHH) is a rare, genetic, reproductive endocrine dis-
order characterized by absent puberty and infertility. Limited information is available on the psychosocial impact of
CHH and psychosexual development in these patients.
Aim. The aim of this study was to determine the impact of CHH on psychosexual development in men on long-term
treatment.
Methods. A sequential mixed methods explanatory design was used. First, an online survey (quantitative) was used
to quantify the frequency of psychosexual problems among CHH men. Second, patient focus groups (qualitative)
were conducted to explore survey ﬁndings in detail and develop a working model to guide potential nursing and
interdisciplinary interventions.
Main Outcome Measures. Patient characteristics, frequency of body shame, difﬁculty with intimate relationships,
and never having been sexually active were assessed. Additionally, we collected subjective patient-reported outcomes
regarding the impact of CHH on psychological/emotional well-being, intimate relationships, and sexual activity.
Results. A total of 101 CHH men on long-term treatment (>1 year) were included for the analysis of the online
survey (mean age 37 ± 11 years, range 19–66, median 36). Half (52/101, 51%) of the men had been seen at a
specialized academic center and 37/101 (37%) reported having had fertility-inducing treatment. A high percentage
of CHH men experience psychosexual problems including difﬁculty with intimate relationships (70%) and body
image concerns/body shame (94/101, 93%), and the percentage of men never having been sexually active is ﬁve times
the rate in a reference group (26% vs. 5.4%, P < 0.001). Focus groups revealed persisting body shame and low
self-esteem despite long-term treatment that has lasting impact on psychosexual functioning.
Conclusions. CHHmen frequently experience psychosexual problems that pose barriers to intimate relationships and
initiating sexual activity. These lingering effects cause signiﬁcant distress and are not ameliorated by long-term
treatment. Psychosexual assessment in CHH men with appropriate psychological support and treatment should be
warranted in these patients. Dwyer AA, Quinton R, Pitteloud N, and Morin D. Psychosexual development in
men with congenital hypogonadotropic hypogonadism on long-term treatment: A mixed methods study. Sex
Med 2015;3:32–41.
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Introduction
Congenital deﬁciency of hypogonadotropichypogonadism (CHH) is an endocrine
disorder resulting from gonadotropin-releasing
hormone (GnRH) deﬁciency. This genetic condi-
tion is clinically characterized by absent puberty
and infertility and may be accompanied by a
variety of associated phenotypes including
cryptorchidism, micropenis, and anosmia (termed
Kallmann syndrome [KS]) [1]. CHH is rare with
incidence estimated at 1 in 4,000–10,000 [2] and
has a striking gender discordance (approximately
2–5 males for each female case) [3,4]. This gender
difference remains genetically unexplained and
may well represent an ascertainment bias as
amenorrheic women presenting for gynecologic
evaluation may likely receive empiric treatment, as
opposed to being referred for an endocrine evalu-
ation [5]. Importantly, CHH patients cannot initi-
ate puberty spontaneously and require hormonal
treatment to develop secondary sexual character-
istics [6]. It is a treatable form of infertility with
approximately 80% of men able to develop sperm
with either pulsatile GnRH or exogenous gonado-
tropin therapy [7–9].
CHH patients typically present to medical
attention with failure to undergo spontaneous
puberty [10]. The challenge being to differentiate
this rare condition from more frequent variants in
the timing and onset of puberty such as constitu-
tional delay of puberty [11,12]. CHH adolescent
males presenting with absent puberty after 14
years of age may be inaccurately deﬁned as “late
bloomers” and their treatment unnecessarily
delayed; the “watchful waiting” approach ﬁnally
ends with the patients re-presenting as pubertal
young adults with frank hypogonadotropic
hypogonadism [10]. As captured in a recent patient
report, such delays in diagnosis can have lasting
psychological and emotional effects on patients
[13].
Puberty is a developmental process character-
ized by numerous physiologic, psychosocial, and
emotional changes culminating in reproductive
capacity. While timing of onset of pubertal devel-
opment is variable, late sexual development can
carry a psychological burden. Delayed puberty can
result in body image concerns, low self-esteem and
social isolation, and later sexual activity [14–16].
Further, many late maturers experience victimiza-
tion or bullying, which are important and common
risk factors for developing depression [17] as well
as other signiﬁcant psychological problems [18].
For CHH men, who represent the most extreme
form of delayed puberty, data on psychological
aspects are limited to a handful of descriptive
case series with few patients [19–21]. Prior to start-
ing treatment, adolescents with CHH exhibit
impaired quality of life and increased anxiety and
depression compared with peers [22,23]. However,
the existing literature has solely focused on the
time of diagnosis or during the initial pubertal
induction and therefore, data regarding the psy-
chosocial impact of CHH in men on long-term
treatment are lacking. Accordingly, we do not
know whether long-term sex steroid treatment
and/or fertility-inducing treatments mitigate the
impact on psychosexual development of CHH
men.
Aim
This study aimed to test the hypothesis that
men with CHH experience psychosexual pro-
blems that are not fully ameliorated by long-term
treatment.
Methods
A community-based participatory research frame-
work [24] was utilized for developing and conduct-
ing this sequential, explanatory mixed method
study [25]. In the context of a European network
focused on CHH/KS (COST Action BM1105),
partnerships with patient community leaders (i.e.,
moderators of online patient support sites) were
developed to include patient perspectives into
the process. Additionally, developing links with
patient support groups was essential for reaching a
sufﬁcient number of patients with this rare condi-
tion. Patient community leaders participated in
developing and improving the language and clarity
of the survey, facilitated recruitment efforts, and
provided feedback on study ﬁndings at each
stage of analysis. This sequential mixed methods
approach employed quantitative methods to iden-
tify the scope and prevalence of issues facing these
dispersed patients followed by qualitative methods
(focus groups) to explore the ﬁndings in greater
detail and to identify possible mechanistic expla-
nations of the survey results. The quantitative
online survey was used to collect patient charac-
teristics and information on diagnosis/treatment
as well as body image, relationship status, and
sexual activity. Subsequently, qualitative patient
focus groups were conducted to explore the impact
of CHH on patients’ lives and psychosexual devel-
Psychosexual Development in CHH 33
Sex Med 2015;3:32–41© 2014 The Authors. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
opment. Focus groups were held in concert with
CHH patient support meetings jointly planned by
patient community leaders and study investigators.
The psychosexual assessment of men with CHH
was part of a larger research project examining
health-promoting behavior [26] and factors affect-
ing quality of life among CHH men. The ultimate
goal of this study is to design innovative nursing
and interdisciplinary interventions to address
unmet health needs in these dispersed rare disease
patients. The study was approved by the Health
Research Ethics Committee (Canton Vaud) and all
participants provided informed consent prior to
the initiation of study-related activities. For the
online survey, an opt-in electronic consent was
used while focus group participants provided
written informed consent.
Subjects
As male patients outnumber female patients in this
rare disorder [3], we focused our attention on male
subjects. Adult CHH men (18–70 years) on treat-
ment for at least 1 year were recruited for the
study. A random sampling (40%) of online survey
respondents was contacted and interviewed to
conﬁrm diagnosis. Those men with other causes of
hypogonadism (i.e., Klinefelter syndrome, adult-
onset hypogonadism) were excluded and surveys
with multiple incomplete or conﬂicting responses
were excluded. The study was publicized online via
a closed/private CHH/KS social media group
(Facebook), CHH/KS forum (chat room), a clini-
cal trials registry, and the COST Action website.
Data from the American National Survey of
Sexual Health and Behavior were used as a com-
parison reference group [27].
Statistics
Survey results were analyzed using descriptive sta-
tistics (mean ± standard deviation, range, median),
Student’s t-test (Wilcoxon rank-sum test for data
not normally distributed) to evaluate differences
between groups, and Z score to assess differences
in proportions between the CHH and the refer-
ence group. SigmaStat (Systat Software Inc., San
Jose, CA, USA) was used for statistical analyses
and a P < 0.05 was considered signiﬁcant.
Qualitative Analysis
Thematic analysis (coding) of focus group tran-
scripts was performed by two separate investiga-
tors (A.A. Dwyer and D. Morin) using NVivo10
(QSR International PSY Ltd., Melbourne, Austra-
lia). Categories of responses and themes were ﬁrst
classiﬁed on the basis of the Health Promotion
Model [26]. Iterative coding occurred until no
further themes were identiﬁed, suggesting a satu-
ration point had been reached. Additionally, con-
nections between coded terms were mapped to
examine connections both within and between cat-
egories (i.e., whether or not certain themes appear
together repeatedly), and those themes arising fre-
quently and expansively were given particular
emphasis [28].
Main Outcome Measures
For the online survey, patient characteristics, age
of diagnosis, age of initiating treatment, frequency
of body shame, difﬁculty with intimate relation-
ships, and never having been sexually active were
the main outcome measures. For patient focus
group discussions, subjective patient-reported
outcomes regarding the impact of CHH on
psychological/emotional well-being, intimate rela-
tionships, and sexual activity were recorded.
Results
The survey was online for 7 months and received a
total of 230 hits of which 101 surveys (44%) were
retained for analysis. The men (mean age 37 ± 11
years, range 19–66, median 36) had all been on
long-term treatment (>1 year) and half (52/101,
51%) had been seen at a specialized or academic
medical center. Participant characteristics and
treatment information are presented in Table 1.
Overall, these men were well educated and
employed and worked across a variety of ﬁelds
and responsibilities (Supporting Information
Table S1). In this cohort, CHHwas diagnosed neo-
natally in four men and as late as 32 years (mean
18 ± 6, median 18 years) (Figure 1). Notably, men
with a familial pattern of inheritance (14/101, 14%)
were not diagnosed earlier than sporadic counter-
parts (P = 0.1) The age of initiating treatment to
develop secondary sexual characteristics ranged
from 11 to 32 years (mean 19 ± 4, median 18 years)
and nearly all men (98/101) had been on some form
of testosterone replacement (injection, implanted
pellets, patches, or gel). Over a third of men (37/
101, 37%) reported having had fertility-inducing
treatment (exogenous gonadotropins or pulsatile
GnRH therapy) with variable outcomes (Table 1).
Nearly a quarter of the men receiving fertility-
inducing treatment (8/37, 22%) were single or had
never been in a relationship, suggesting a motiva-
tion for pursuing these time and resource-intensive
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programs extended beyond an immediate desire to
achieve fertility. Those CHH men with children
were older than thosewithout children (median age
43.5 vs. 32.0 years, P < 0.001).
Despite Long-Term Treatment, a High Proportion of
CHH Men Have Psychosexual Problems
As no data are available on the sex lives of men on
long-term treatment, we asked participants if they
had ever been sexually active. Notably, 26/101
(26%) of men reported they had never been sexu-
ally active. This is nearly ﬁve times the rate (26%
vs. 5.4%, P < 0.001) observed in adult men (18+
years) in a large (n > 2,000) probability survey
examining sexual activity [27]. During survey
development, discussions with patient community
leaders suggested that traumatic experiences, body
image concerns, and difﬁculty with intimate rela-
tionships were frequently raised in private, online
discussions. When we inquired about these points,
72% (73/101) stated that they had been teased or
ridiculed because of CHH and 93% (94/101)
reported that they had felt embarrassed or
ashamed of their body and avoided undressing in
public such as at the gym or beach. Further, 70%
(69/99) of men agreed that intimate relationships
were difﬁcult because of CHH. Neither age of
diagnosis nor age of treatment initiation was sig-
niﬁcantly related to any of these results. We
hypothesized that concerns about testicular size
could be a factor in these ﬁndings, yet no differ-
ences were observed between those men who had
received fertility-inducing treatment (inducing
testicular growth) and those men on testosterone
only (no testicular development). These data point
to a signiﬁcant impact of CHH on the psycho-
sexual development. To explore this in greater
detail, we conducted three patient focus groups.
These discussions provided further insight into the
survey ﬁndings and helped explain the lasting psy-
chosexual impact of CHH that pose barriers to
dating, developing intimate relationships, and ini-
tiating sexual activity.
CHH-Related Body Shame Has Lasting Impact on
Psychosexual Functioning
Patient focus group discussions grew from two
questions: “What has been the most difﬁcult part
of living with CHH?” and “How has CHH
affected your sex life and intimate relationships?”
Twenty-six men participated in the focus groups
(mean age 37 ± 13 years, range 18–66, median 36
years) revealing consistent, overarching themes of
shame and isolation related to CHH. Patients fre-
quently cited their frustration at what they per-
ceived as a late diagnosis and thus did not have
puberty induced until much later than their peers.
More speciﬁcally, patients reported their sense
Table 1 Sociodemographic and treatment information of
CHH men (n = 101)
Age n
19–29 years 30
30–39 years 38
40–49 years 19
50–59 years 11
60+ yrs 3
Education
High school/vocational 35
University 35
Postgraduate 31
Employment
Working full-time 67
Working part-time 9
Unemployed 10
Retired 5
Student 9
No response given 1
Relationship status
Married 36
In a relationship 16
Single 24
Never been in a relationship 23
Divorced 1
No response given 1
Children
None 75
Biologic children 8
Adopted children 18
Treatment n (%)
Testosterone (ever) 98/101
Fertility treatment* 37/101
Single/never in a relationship 8/37 (22%)
No children 14/29 (48%)
Adopted children 7/29 (24%)
Biological children 8/29 (28%)
*Gonadotropin therapy or pulsatile GnRH therapy.
CHH = congenital hypogonadotropic hypogonadism; GnRH = gonadotropin-
releasing hormone.
Figure 1 Age at diagnosis in the cohort of congenital
hypogonadotropic hypogonadism (CHH) men (n = 101).
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of isolation resulted from their absent sexual
development and feeling “left behind” as peers
developed physically, became sexual active, and
assumed adult roles (Figure 2, Table 2). This mar-
ginalization fed fears of being exposed and many
(20/26) attempted to hide their lack of puberty by
avoiding situations possibly involving nudity and
in some cases, avoiding social events. Problems
with body image dominated focus group discus-
sions both in terms of the number of comments
and the proportion of participants (23/26) report-
ing body shame (Figure 2, Table 2).
Similar to the literature on late maturing ado-
lescent boys [14–17] and the online survey results,
men in the focus groups reported traumatic
experiences including teasing, victimization, and
bullying related to their youthful appearance,
underdeveloped genitalia and in some cases,
gynecomastia resulting from CHH. Notably,
despite virilization on long-term hormone treat-
ment, these men struggled to overcome a self
image of the undeveloped, youthful adolescent of
their past. These negative thoughts persisted well
into adulthood—even though many realized that
these thoughts were not rational. Discussions
revealed a cycle of isolation and shame wherein
hiding and removing oneself from social situations
only worsened the body image and self-esteem
issues (Figure 2, Table 2).
Importantly, patients reported ameliorating
factors that helped them cope with their disrupted
psychosexual development including meeting
other patients with CHH (Table 2). In total, 15/26
men provided unsolicited comments stating that
this was a life-changing event enabling them to
overcome some of their feelings of shame and iso-
lation. Half of the men (13/26) shared that coping
with the psychosexual aspects of CHH became
easier with age and that this was often related to
ﬁnding someone who accepted them as they are
(i.e., an understanding healthcare provider, thera-
pist, partner, or spouse). These highlight potential
interventions such as connecting patients for peer-
to-peer support.
Limitations
This type of study has inherent limitations includ-
ing limited sample size. First, studying rare disease
populations pose challenges for recruiting adequate
number of patients [29,30]. We attempted to over-
come this by using web-based data collection via an
online survey. This approach introduces potential
bias as not everyone has internet access, so this
convenience sample may be enriched with well-
educated men and may reﬂect a response bias of
more proactive and/or more severely affected
patients. Second, participants were recruited via
expert clinicians as well as among patient support
groups. Because medical chart review of this dis-
persed disease population was beyond the scope
this study, we recontacted 40% of respondents to
conﬁrm diagnosis. Thus, we cannot be sure that
every respondent met all hormonal and clinical
criteria of a CHH diagnosis. Importantly, the ﬁnd-
ings of the survey were mirrored in the focus group
discussion (where all participants had conﬁrmed
CHH diagnosis), thus contributing to the validity
of the study. Last, as no validated questionnaire is
available for CHH men to assess health-related
quality of life or sexual function [31], we developed
our own questionnaire. Face validity was sought
with input from patient advocates, but a full valida-
tion process was not performed.While validity and
reliability in self-report responses are important,
there is a growing acceptability of using patient-
reported outcomes for managing chronic condi-
tions [32]. Further, using focus groups with expert
patients to explore these is an added value to the
validity of the results.
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Figure 2 Focus group themes related to the impact of dis-
rupted sexual maturation on psychosexual development
and intimate relationships. (A) Focus group participants
reported feeling isolated and “left behind” as peers under-
went sexual development, started dating, and began taking
on more adult roles. (B) Patients often developed fear and
anxiety about being exposed and tried to hide their lack of
sexual development as a coping response. (C) Body shame
and body image concerns were the most frequently cited
issues which co-occurred with low self-esteem. These
issues interacted with existing fears/anxiety creating a cyclic
pattern with effects lasting far after treatment initiation.
Circles depict themes from focus group discussions, circles
are sized proportionally with the number of references,
overlapping circles depict co-occurring themes, and inter-
actions are noted by arrows.
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Table 2 Themes and representative quotes arising from focus group discussions
Theme Representative quotes
Feeling left behind
(isolation)
• “I was diagnosed at 23. So, that’s why I say I ‘missed out’ on that 17–20 (years of age) physical and emotional
development. I think that is where people miss-out on a lot . . . and not being able to catch up.”
• “Watching your sisters, your younger sisters and younger cousins and watching them pass you while you are left behind
right now is still emotionally traumatic. It’s just the little stuff like that . . . it all builds.”
• “I was dependent on a nurse who injected my treatment twice a week, and people all around me experiencing their young
adult life . . . independence from parents, sentimental and sexual relationships, a night out . . . all that discovery was out of
reach for me for unfair reasons.”
Fear of being
exposed
• “Fear of exposure was the biggest thing for me . . . especially when I was younger in middle school and through high
school. I was afraid to go into the bathroom and pee in the urinal.”
• “(around 15 years old) I was forced to take gym class and I feared that I would be noticed. I knew I would be ridiculed
mercilessly if anyone found out. I vowed that I would not use the shower after gym class no matter what.”
• “(communal showers) It was like doing anything to get out of a shower . . . I would try anything. In fact, I would just come
out of the gym and just not shower. You know, just put my clothes on over my gym shorts and stuff like that. But it’s that
. . . fear of exposure.”
• “I would purposefully forget (gym clothes) so I wouldn’t have to take physical education so I wouldn’t have to shower. And
the teacher would go to the lost property and find a spare and try to force me to wear it so that I could take part. So, I
would be in detention . . . god knows how many times.”
Hiding • “(during teen years) I was doing my best to remain as inconspicuous as possible and not have my condition discovered . . .
nothing else mattered.”
• “You spend so much of your adolescence and your late teens, 20s hiding stuff. You are hiding the fact that you can’t smell,
you are kind of covering over that, you are hiding that you don’t want to shower, it’s just so much hiding that there’s almost
an emotional reticence. And, I think that translates into relationships too.”
• “For me it has been shame. Yeah, that has been the hardest part. And so . . . I kind of isolated myself, staying indoors, and
that has led to a kind of social anxiety. So, I don’t really have any friends really . . . that’s given the most impact on my life.”
Body shame/poor
body image
• “I haven’t been intimate with anyone in over 10 years. I don’t have any friends, I don’t have a girlfriend . . . I have kind of
accepted that I won’t have any girlfriends or friends. I’m just ashamed of my body.”
• “(regarding dating) You think down the road and wonder if this eventually goes anywhere . . . I don’t want to undress in front
of this person.”
Body shame/poor
body image
• “My biggest thing was about having Kallmann’s (CHH) was genital size. That’s the only thing that was affected . . . and
been an issue. Which I know is very superficial and is probably a bit silly, but that’s me. It’s always sort of there, you’re
always sort of consciously aware of it.”
• “There’s extreme shame about having small genitalia . . . it’s just extreme for me.”
• “We are probably hung a bit less-well than most people. It can be a bit . . . you know, if a woman . . . if you drop your
trousers and a woman bursts out laughing, it’s just devastating. What do you do?”
• “I was always ashamed of that stuff (body and gynecomastia). It was insidious, sometimes I was seen as a girl . . . you
know, is that a boy or a girl?”
Low self-esteem • “I felt ashamed really . . . I withdrew from it, from everything really. So, it’s the same I don’t really have any friends really,
not a lot of social contact or anything like that.”
• “It (CHH) is always with me . . . very, very low self-esteem, massively low confidence . . . you know, I have done all the
educational stuff, I’ve got a good job. Even after 20+ years with the same company, my confidence level at my work is still
very, very low. I tend to mask it sometimes, in that sort of situation but in reality, I’m in quite a fragile state . . . it doesn’t
take much to sort of push me down.”
• “For a long time even after starting treatment, I knew I was physically as normal as a man can be . . . (but) I was unable to
seduce a woman . . . very difficult to deal with the potential rejection . . . still thinking she would see a kid who should not
do what he is doing. I had a total lack of confidence in this aspect of my life.”
Lingering effects • “All of those things are seeds for psychological damage. I mean the stuff occurring at that stage builds up and builds up
and builds up over the years . . . it lingers for sure.”
• “You may have all the outward appearances (of puberty), but here (pointing to head) . . . as far as I’m concerned, I’m still
different. It’s almost as though one day, someone is going to see right through it, and they’ll know . . . it’s that fear.”
• “Basically as a Kallmann (CHH) patient I spent most of my early adult life building barriers and walls to others to avoid
being emotionally hurt and keep mental sanity. It worked . . . but later on in my life, these survival skills were totally
irrelevant and became the main problem.”
• “I still have a hard time with public nudity . . . I wouldn’t join a gym that had an open shower . . . so like there are even
these lingering psychological that affect me even today but they are not as severe as when I was younger.”
• “I’m wondering is if we have some overlap with a PTSD (posttraumatic stress disorder), there might be some things that are
still things that will trigger flashbacks.”
• “I was forever looking back at as far as I could see . . . a lost 16 years. As I’ve grown older, it’s not just the 16 years.
There’s actually a lot, lot more than that. The older I get, the focus is perhaps not on looking back but looking forward. And
that . . . is just as negative for me sometimes as it is looking back. As far as I’m concerned, it never, ever leaves me . . .”
Mediating factors • “I have found the groups on Facebook and that, you know . . . starting to talk to people. That’s the only thing that has really
helped me so far for coming to terms with it (CHH).”
• “It wasn’t until I found other people like (patient community leader) and such that I kind of filled in the blanks a bit. It was
quite isolating for me and I had no one to talk to and I felt like I was the only person in the world to have this problem you
know?”
• “The two major things for me have been having somebody love me and not see as no different from any other man . . . and
this, meeting other people face to face, being able to talk and email people and just . . . you know . . . (other patient) has
been exceptionally caring to me.”
• “When I was in my teens and 20s it was harder . . . it does get a little easier, but still there’s a lot of emotional scars.”
• “It’s like, you can answer those questions (for young CHH patients) and say: look, it’s going to be tough for a couple of
years . . . but, you know, it’s going to get better.”
• “Learning about it (CHH) made me feel that Kallmann (CHH) is not such a big deal. But in my case, it was not enough and
the psychotherapy aspect helped a lot . . . I’m not sure I’d be as satisfied without.”
CHH = congenital hypogonadotropic hypogonadism.
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Discussion
We report evidence of persisting psychosexual
impact of CHH that is not ameliorated by long-
term hormone replacement therapy. CHH is a
rare disorder that has been previously used as a
unique human disease model providing important
insights into the hormonal control of the
hypothalamic–pituitary–gonadal axis [33,34].
Further, genetic studies on this extreme form of
delayed puberty have informed our understanding
of the molecular control of human puberty and
reproduction [1,35]. However, there are scant data
on how the severe disruption of puberty impacts
psychosexual development in CHH men.
Previous reports on the psychosocial aspects of
CHH include several descriptive case series of
small cohorts of CHH men during initial treat-
ment. The 1964 report of eight cases of so-called
“sexual infantilism” (including three CHH men
20–47 years of age) commented on embarrassment
because of youthful appearance and feelings of
sexual inadequacy [19]. A subsequent 1971 report
documenting 13 cases from the Johns Hopkins
University Hospital added observations on insecu-
rity, decreased conﬁdence, and low interest in
dating among 13 CHHmen (19–44 years old) after
starting treatment [20]. Another study published in
1996 followed eight CHH men initiating pulsatile
GnRH therapy for pubertal induction noting
diminished social interactions and poorer views of
their physique compared with controls [21]. In the
present study, we examined these issues in a rela-
tively large cohort of CHH men (n = 101), provid-
ing data on the prevalence of these issues. We then
conducted focus groups to develop an explanatory
model for these observations, thus enhancing our
understanding of the unmet psychological and psy-
chosexual needs of CHH men in order to better
direct therapy and interventions.
In contrast to prior studies, we focused exclu-
sively on men receiving long-term treatment to see
if psychosocial and psychosexual issues are cor-
rected by a longer period with a normalized sex
steroid milieu. Testosterone replacement therapy
has long been shown to be effective for inducing
secondary sexual characteristics and normalizing
sexual function [6] and has well-documented ben-
eﬁcial effects on muscle and fat-free (lean) body
mass [36] as well as mood [37]. The CHH men on
long-term treatment in this study struggled with
psychosocial aspects of their condition. Thus, it
seems that hypogonadal patients should ﬁrst
receive testosterone replacement then be offered
psychosexual help to address these needs. Impor-
tantly, focus group discussions revealed CHH men
are challenged to perceive themselves as a normal-
appearing virilized men. This may relate to a form
of body dysmorphic disorder (BDD) wherein indi-
viduals develop an altered view of personal appear-
ance [38]. BDD has been linked with early
traumatic life events [39] and can have signiﬁcant
impact on quality of life [40]. As BDD appears to
be responsive to cognitive behavioral interven-
tions, similar approaches may be warranted for
CHH men to address their signiﬁcant body image
concerns.
A surprising ﬁnding was that fertility was never
raised as a major concern within focus group dis-
cussions. Rather, attention centered on body shame
and lack of genital development. Testosterone
replacement induces secondary sexual characteris-
tics and normalizes sexual function yet has no effect
on testicular development and testis volume
remains small (infantile in some cases). We found
that 22% of men who had received fertility-
inducing treatment had never been in a relation-
ship. While the survey was not designed to
speciﬁcally determine the motivation for choosing
speciﬁc treatments, this observation suggests that
these treatments were pursued to augment testi-
cular volume and thus normalize genital appear-
ance. Indeed, it would be interesting to utilize the
recently developed genital self-image scale [41] to
better understand how these factorsmay contribute
to these men’s sexual experiences and why they are
ﬁve times more likely to never have been sexually
active. Some have speculated that the atrophic
testes and/or severely diminished phallus size
sometimes associated with CHH can have serious
negative effects on self-conﬁdence and the sexual
life of CHH men [6,10,42]. Herein, we provide
direct evidence supporting these assertions.
Micropenis (with or without cryptorchidism)
can be associated with CHH. We did not assess
how many men were born with micropenis as
this can be difﬁcult to ascertain in the absence
of medical documentation. However, outcome
studies of patients with micropenis indicate dimin-
ished penis size persisting into adult life can have
negative consequences on sexual quality of life
[43]. Related to this, concern about penis size was
pervasive and a frequently occurring topic in focus
group discussions. Indeed, in every focus group
patients made spontaneous inquiries regarding
normative ranges for penis size among CHH men.
While population-based normative data are avail-
able on penis size [44], corresponding data on a
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large cohort of CHH are lacking. CHHmen expe-
rience signiﬁcant preoccupation and shame
regarding penis size. Accordingly, it could be
useful to evaluate this using a validated instrument
[45] before and after providing reference ranges
for this patient population along with targeted
cognitive behavioral interventions to address these
body shame issues. Such an approach could be a
possible avenue for alleviating this distressing
problem for CHH men. The ultimate goal of this
study was assess impact of CHH on psychosexual
development in order to identify patient needs and
design innovative nursing and interdisciplinary
interventions for these dispersed patients. Impor-
tantly, one result of this study was that conducting
patient focus groups brought together isolated
patients and provided them with an opportunity to
discuss these problems, share experiences, and
seek support—which in and of itself was an impor-
tant and empowering intervention for these
patients.
Conclusions
This mixed methods study presents data demon-
strating the pervasive psychosexual difﬁculties
experienced by CHH men on long-term treat-
ment. The CHH-related absent sexual develop-
ment has lasting effects that pose barriers to
intimate relationships and initiating sexual activity.
Further, the psychosocial distress experienced by
CHH men is not ameliorated by long-term treat-
ment. These ﬁndings underscore the importance
of psychosexual assessment of CHH men and the
need for psychological support and interdisciplin-
ary care for this patient population.
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